checkAd

     135  0 Kommentare NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - Seite 3 

    CONTACT: Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com

Media Inquiries
Emily Wong
MacDougall
(781) 235-3060
NextCure@macbiocom.com


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von globenewswire
    NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - Seite 3 BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today …